Navigation Links
Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
Date:3/26/2008

ede and can develop into cervical cancer. The primary cause of such abnormalities is infection with certain HPV types, of which HPV-16 is the most common. In the U.S., these infections are typically discovered through nearly 60 million Pap screens completed each year, at a cost of up to $6 billion. Each year in the U.S., an estimated 1.2 million women are diagnosed with low grade cervical dysplasia, (CIN 1), 300,000 with high grade dysplasia (CIN 2/3) and 2.4 million with atypical squamous cells of undetermined significance (ASCUS). No therapies other than surgery are currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of any type of CIN.

About HspE7:

The company's lead candidate, HspE7, is a novel therapeutic candidate intended for the treatment of precancerous and cancerous lesions caused by the human papillomavirus (HPV), one of the most common sexually transmitted diseases in the world. HspE7 incorporates the proprietary adjuvant, Poly-ICLC, a toll-like receptor-3 (TLR3) agonist. An adjuvant is a substance added to vaccines to improve immune responses against target antigens. HspE7 is derived from Nventa's proprietary CoVal(TM) fusion platform, which uses recombinant DNA technology to covalently fuse stress proteins to target antigens, thereby stimulating cellular immune system responses. Nventa is developing HspE7 for multiple indications.

About Nventa Corporation:

Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). The company is publicly traded on the Toronto Stock Exchange under the symbol NVN. For more information about Nventa, please visit http://www.nventacorp.com.

This press release contains statements which may constitute forward-looking information under applicable Canadian securities legislation or forward-looking statements
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
3. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
4. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
5. IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study
6. Valor Medical Announces First Human Implant of Neucrylate AN(TM) for Treatment of Cerebral Aneurysm
7. Medicare Announces Expanded Coverage for Anticoagulation Patients, Opening the Door for More Patients to Test PT/INR at Home
8. Medicare Announces Expanded Coverage for Warfarin Patients Monitoring Clotting Time at Home
9. FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
10. Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses
11. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... LEWIS CENTER, Ohio , May 22, 2013 ... of Opioid Defense Manager™ (ODM).  Launched in November ... Medical,s revolutionary managed care program to stop the ... ODM is a proactive, customized program designed to ... drug use while maintaining the necessary balance to ...
(Date:5/22/2013)... -- Z-Medica, a leading developer and marketer of hemostatic ... of products designed to meet the unique needs of ... EMS 4x4 Dressing, QuikClot ® EMS TraumaPad ® ... custom-designed to help responders stop bleeding fast and keep ... hospital or trauma center. The line includes products designed ...
(Date:5/22/2013)... MAPLE GROVE, Minn. , May 22, ... today announced the successful completion of its ... (extended-release topiramate), an internally developed program for ... the company,s proprietary formulation technology.  USL255 is ... and reduce fluctuations in topiramate blood levels ...
Breaking Medicine Technology:Modern Medical Introduces Opioid Abuse Solution to the Workers' Compensation Industry 2Z-Medica Launches New Line of Hemostatic Agents for use in Emergency Medical Services 2Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 2Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 3Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 4
... SAN DIEGO, Feb. 18, 2011 Zimmer Holdings, Inc. (NYSE: ... care, today announced it has received FDA clearance for the ... TM-S system is the industry,s first cervical interbody device incorporating ... device for cervical interbody fusion (IBF) in the United ...
... Bellicum Pharmaceuticals, Inc. today announced the presentation ... BPX-101, a novel drug-activated dendritic cell vaccine for ... separate posters at the 2011 Genitourinary Cancers Symposium ... 19, 2011. Three leading medical specialty societies co-sponsor ...
Cached Medicine Technology:Zimmer Spine Introduces Industry's First Porous Metal Cervical Interbody Device 2Zimmer Spine Introduces Industry's First Porous Metal Cervical Interbody Device 3Clinical Responses Demonstrated in Metastatic Castrate Resistant Prostate Cancer Patients Treated With BPX-101 Cancer Vaccine 2Clinical Responses Demonstrated in Metastatic Castrate Resistant Prostate Cancer Patients Treated With BPX-101 Cancer Vaccine 3
(Date:5/22/2013)... Brook, New York (PRWEB) May 22, 2013 ... that specializes in combining treatments for optimal results, is ... thin skin on the neck. The practice has ... seen dramatic results. , “Basically, this approach is for ... lift,” says Westchester dermatologist Dr. Michelle Abadir ...
(Date:5/22/2013)... of the antidepressant Lexapro appears to help prevent ... study finds. The condition is known ... people with this condition may not develop noticeable ... blood supply, according to researchers from Duke University ... the researchers found that people taking the antidepressant ...
(Date:5/22/2013)... research from Brigham and Women,s Hospital (BWH) finds that ... but deadly lung disease, may be effective in identifying ... will be presented at the American Thoracic Society International ... England Journal of Medicine on May 22 and ... "While this variant of the MUC5B gene is fairly ...
(Date:5/22/2013)... May 22, 2013 The PreDiabetes Center ... participation in the Greater Philadelphia Tour de Cure, a premier ... who are passionate about stopping the spread of diabetes ... Americans. , The Tour de Cure will take place ... Meetinghouse Road in Ambler, 30 minutes outside of Philadelphia, between ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Following the ... fitness franchise Fit Body Boot Camp Kincardine ... 1,000 lb. Meltdown Challenge starting on June 3rd at ... Centre 601 Durham Street, Kincardine, Ontario.     , Fit Body ... inspire and motivate local community residents to lose a ...
Breaking Medicine News(10 mins):Health News:Westchester Dermatologist Abadir Associates Offers New Neck Lift Surgery Alternative 2Health News:Antidepressants May Be Helpful for Some Heart Patients: Study 2Health News:Antidepressants May Be Helpful for Some Heart Patients: Study 3Health News:Genetic marker associated with risk for pulmonary fibrosis 2Health News:PreDiabetes Centers to Appear at the Philadelphia Tour de Cure 2Health News:PreDiabetes Centers to Appear at the Philadelphia Tour de Cure 3Health News:Kincardine Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 2Health News:Kincardine Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 3
... Favorite, and ,Have Fun Helping It ... ... Recession? Killer bees? No! Only positive predictions, please.,That,s the attitude of Richard ... debut last month., *(PHOTO 72dpi: Send2Press.com/mediaboom/07-1115-DSamson_72dpi.jpg), *(Photo Caption: SuperLife founder ...
... /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, Inc. (OTC Bullion ... medicinal and diagnostic products in China,today announced that ... Company,s Form 10QSB for the fiscal quarters ended ... filed its full year 2006 amendments on,November 8, ...
... 18 Escalon Medical Corp.,(Nasdaq Capital Market: ESMC) ... clearance from the U.S. Food and Drug,Administration (FDA) ... differential Hematology Analyzer. Drew Scientific plans to,commence shipments ... month-end., "The FDA clearance represents a major ...
... PHILADELPHIA A new brain imaging study by researchers ... Pennsylvania shows that cigarette cravings in smokers who are ... specific regions of the brain. Using a novel method ... MD, associate professor of Neurology at Penn, this study ...
... (NYSE: CDI ),announced today that the Life ... been awarded a contract from CJ CheilJedang,Corporation to ... manufacturing complex to be located in Osong, Korea. ... center for global,distribution of oral solid and sterile ...
... where he worked as a ... ... Dikembe,Mutombo, who is known as much for his philanthropy as his storied ... organization prepare its entry into his home country, the,Democratic Republic of Congo ...
Cached Medicine News:Health News:Six Positive Predictions for 2008, from SuperLife World Service 2Health News:China Sky One Medical Completes Previously Announced Amendments to Form 10QSB for the Second and Third Quarters of 2006 2Health News:Escalon(R) Announces FDA 510(K) Clearance for D3 Hematology System 2Health News:Escalon(R) Announces FDA 510(K) Clearance for D3 Hematology System 3Health News:New neuroimaging study identifies 'brain signature' for cigarette cravings 2Health News:CDI-Life Sciences Selected by CJ CheilJedang Corp. to Provide Engineering Design for Major Pharmaceutical Complex in Korea 2Health News:NBA Legend Dikembe Mutombo Joins Opportunity International Board of Advisors; Opens Doors in Democratic Republic of Congo 2Health News:NBA Legend Dikembe Mutombo Joins Opportunity International Board of Advisors; Opens Doors in Democratic Republic of Congo 3Health News:NBA Legend Dikembe Mutombo Joins Opportunity International Board of Advisors; Opens Doors in Democratic Republic of Congo 4
... the hand, the Jarvik 2000 pump is about ... welded titanium shell sits a direct-current motor, a ... single moving part: a small, spinning titanium impeller ... to 7 liters per minute. Rather than take ...
... cardiac assist system primarily designed as a permanent ... failure., ,It is a blood pump that connects ... to help the ailing hearts pumping function and ... , ,It can also be used as a ...
... The Masimo SET LNOP Blue Sensor is ... babies. The LNOP Blue sensor is ... accuracy claims for cyanotic infants and children. ... presented challenging conditions for reliable and accurate ...
... The Trinity Biotech Captia™ Varicella-Zoster Virus (VZV) ... for the detection and quantitative determination of ... Individual serum specimens may be used for ... acute and convalescent, may be used to ...
Medicine Products: